- Current report filing (8-K)
2012年5月26日 - 5:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) May 23, 2012
MEDIFAST, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
000-23016
|
13-3714405
|
(State or Other Jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
11445 Cronhill Drive
,
Owing Mills, Maryland
|
21117
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
Registrant's telephone number, including
area code
(410)-581-8042
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events
The Board of Directors of Medifast, Inc. authorized, as disclosed
in prior Current Reports on Form 8-K, the repurchase of up to 1,000,000 shares of the Company’s common stock. Pursuant to
that authority, on May 23, 2012 and May 24, 2012, the Company purchased a total of 150,000 shares of common stock at an average
price of $18.34 per share, aggregating $2,764,000. There are 125,000 remaining authorized shares which may be purchased under the
repurchase program.
Stock repurchases under this program have been made by
the Broker through open market and privately negotiated transactions at times and in such amounts as management deemed
appropriate pursuant to Rule 10b-18 of the Exchange Act. The timing and actual number of shares repurchased will depend on a
variety of factors including price, corporate authorization provisions, above noted regulatory requirements, and other market
conditions.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly
authorized.
|
MEDIFAST, INC.
|
Dated: May 25, 2012
|
|
|
By
|
/s/ Brendan N. Connors
|
|
|
Brendan N. Connors
Chief Financial Officer
|
Medifast (NYSE:MED)
過去 株価チャート
から 6 2024 まで 7 2024
Medifast (NYSE:MED)
過去 株価チャート
から 7 2023 まで 7 2024